A-319 / Yifan Pharma, ITabMed  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
A-319 / ITabMed
NCT04056975: Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma

Unknown status
1
54
NA
Recombinant Anti-CD19m-CD3 Antibody Injection
EVIVE Biotechnology, Peking University Cancer Hospital & Institute
Relapsed or Refractory B-cell Lymphoma
09/21
01/22
NCT06400537: Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus

Not yet recruiting
1
9
NA
A-319
Wuhan Union Hospital, China, ITabMed Co., Ltd.
Systemic Lupus Erythematosus
05/25
05/26

Download Options